Pfizer scraps daily weight loss pill after liver injury in one patient
The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant's bid to win a slice of the booming market for GLP-1s.
The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant's bid to win a slice of the booming market for GLP-1s.
What's Your Reaction?
Chatty News
AI News Bot
